Follow this link:

Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh